{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:54:34Z","timestamp":1773150874264,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s00277-020-04060-z","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T09:03:12Z","timestamp":1588842192000},"page":"1257-1264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long PFS of more than 7\u00a0years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Roussou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-2447","authenticated-orcid":false,"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3407-5994","authenticated-orcid":false,"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"key":"4060_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC (2017) Multiple myeloma. Nat Rev Dis Primers 3:17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46","journal-title":"Nat Rev Dis Primers"},{"key":"4060_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/ijc.32232","volume":"146","author":"MA Castaneda-Avila","year":"2019","unstructured":"Castaneda-Avila MA, Ortiz-Ortiz KJ, Torres-Cintron CR, Birmann BM, Epstein MM (2019) Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013. Int J Cancer 146:35\u201343. https:\/\/doi.org\/10.1002\/ijc.32232","journal-title":"Int J Cancer"},{"issue":"20","key":"4060_CR3","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J (2014) Curing myeloma at last: defining criteria and providing the evidence. Blood 124(20):3043\u20133051. https:\/\/doi.org\/10.1182\/blood-2014-07-552059","journal-title":"Blood"},{"issue":"4","key":"4060_CR4","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/HS9.0000000000000045","volume":"2","author":"SGR Verelst","year":"2018","unstructured":"Verelst SGR, Blommestein HM, De Groot S, Gonzalez-McQuire S, DeCosta L, de Raad JB, Uyl-de Groot CA, Sonneveld P (2018) Long-term outcomes in patients with multiple myeloma. A retrospective analysis of the Dutch population-based HAematological registry for observational studies (PHAROS). HemaSphere 2(4):e45. https:\/\/doi.org\/10.1097\/HS9.0000000000000045","journal-title":"HemaSphere"},{"issue":"7","key":"4060_CR5","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17474086.2016.1195254","volume":"9","author":"S Jagannath","year":"2016","unstructured":"Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D (2016) Real-world treatment patterns and associated progression-free survival in relapsed\/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol 9(7):707\u2013717. https:\/\/doi.org\/10.1080\/17474086.2016.1195254","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"4060_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, Rajkumar SV (2018) Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 8(3):26. https:\/\/doi.org\/10.1038\/s41408-018-0065-8","journal-title":"Blood Cancer J"},{"issue":"15","key":"4060_CR7","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412\u20133420. https:\/\/doi.org\/10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"},{"issue":"26","key":"4060_CR8","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863\u20132869. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"issue":"2","key":"4060_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/leu.2011.204","volume":"26","author":"KD Boyd","year":"2012","unstructured":"Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ, Group NHOS (2012) A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC myeloma IX trial. Leukemia 26(2):349\u2013355. https:\/\/doi.org\/10.1038\/leu.2011.204","journal-title":"Leukemia"},{"issue":"1","key":"4060_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G (2019) A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 33(1):159\u2013170. https:\/\/doi.org\/10.1038\/s41375-018-0196-8","journal-title":"Leukemia"},{"issue":"7","key":"4060_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn C, Davies FE (2019) Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 133(7):660\u2013675. https:\/\/doi.org\/10.1182\/blood-2018-09-825331","journal-title":"Blood"},{"issue":"6","key":"4060_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ (2018) Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 132(6):587\u2013597. https:\/\/doi.org\/10.1182\/blood-2018-03-840132","journal-title":"Blood"},{"issue":"9","key":"4060_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","volume":"17","author":"C Pawlyn","year":"2017","unstructured":"Pawlyn C, Morgan GJ (2017) Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 17(9):543\u2013556. https:\/\/doi.org\/10.1038\/nrc.2017.63","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"4060_CR14","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00330-016-4543-8","volume":"27","author":"SY Lee","year":"2017","unstructured":"Lee SY, Kim HJ, Shin YR, Park HJ, Lee YG, Oh SJ (2017) Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis. Eur Radiol 27(6):2333\u20132347. https:\/\/doi.org\/10.1007\/s00330-016-4543-8","journal-title":"Eur Radiol"},{"issue":"1","key":"4060_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","volume":"132","author":"L Rasche","year":"2018","unstructured":"Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132(1):59\u201366. https:\/\/doi.org\/10.1182\/blood-2018-04-842880","journal-title":"Blood"},{"issue":"6","key":"4060_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","volume":"33","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E (2015) Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 33(6):657\u2013664. https:\/\/doi.org\/10.1200\/JCO.2014.57.9961","journal-title":"J Clin Oncol"},{"issue":"1","key":"4060_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E (2014) Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 25(1):195\u2013200. https:\/\/doi.org\/10.1093\/annonc\/mdt483","journal-title":"Ann Oncol"},{"issue":"6","key":"4060_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.49","volume":"7","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas DC, Migkou M, Panagiotidis I, Eleutherakis-Papaiakovou E, Kanellias N, Psimenou E, Marinaki S, Bacharaki D, Mparmparoussi D, Matsouka C, Giannouli S, Terpos E, Kastritis E (2017) Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J 7(6):e571. https:\/\/doi.org\/10.1038\/bcj.2017.49","journal-title":"Blood Cancer J"},{"issue":"13","key":"4060_CR19","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E (2016) International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34(13):1544\u20131557. https:\/\/doi.org\/10.1200\/JCO.2015.65.0044","journal-title":"J Clin Oncol"},{"issue":"8","key":"4060_CR20","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","volume":"32","author":"A Larocca","year":"2018","unstructured":"Larocca A, Dold SM, Zweegman S, Terpos E, Wasch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M (2018) Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia 32(8):1697\u20131712. https:\/\/doi.org\/10.1038\/s41375-018-0142-9","journal-title":"Leukemia"},{"issue":"2","key":"4060_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2):91\u201397. https:\/\/doi.org\/10.1056\/NEJM199607113350204","journal-title":"N Engl J Med"},{"issue":"19","key":"4060_CR22","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working P (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875\u20131883. https:\/\/doi.org\/10.1056\/NEJMoa022340","journal-title":"N Engl J Med"},{"issue":"6","key":"4060_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","volume":"24","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24(6):929\u2013936. https:\/\/doi.org\/10.1200\/JCO.2005.04.5807","journal-title":"J Clin Oncol"},{"issue":"12","key":"4060_CR24","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","volume":"106","author":"J Blade","year":"2005","unstructured":"Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J, Mateos MV, Palomera L, Fernandez-Calvo J, Marti JM, Giraldo P, Carbonell F, Callis M, Trujillo J, Gardella S, Moro MJ, Barez A, Soler A, Font L, Fontanillas M, San Miguel J, Programa para el Estudio de la Terapeutica en Hemopatia M (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106(12):3755\u20133759. https:\/\/doi.org\/10.1182\/blood-2005-03-1301","journal-title":"Blood"},{"issue":"36","key":"4060_CR25","doi-asserted-by":"publisher","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","volume":"23","author":"JP Fermand","year":"2005","unstructured":"Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, Group M-A (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23(36):9227\u20139233. https:\/\/doi.org\/10.1200\/JCO.2005.03.0551","journal-title":"J Clin Oncol"},{"key":"4060_CR26","doi-asserted-by":"publisher","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","volume":"82","author":"I Ntanasis-Stathopoulos","year":"2020","unstructured":"Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, Dimopoulos MA (2020) Multiple myeloma: role of autologous transplantation. Cancer Treat Rev 82:101929. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101929","journal-title":"Cancer Treat Rev"},{"key":"4060_CR27","doi-asserted-by":"crossref","unstructured":"Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, Gika D, Fotiou D, Kanellias N, Ziogas D, Ntanasis-Stathopoulos I, Barbarousi D, Gatou A, Katopi D, Manios E, Liontos M, Giannouli S, Tsirigotis P, Terpos E, Dimopoulos MA (2019) Early relapse post autologous transplant is associated with very poor survival and identifies an ultra high risk group of myeloma patients. Clin Lymphoma Myeloma Leuk [in press]","DOI":"10.1016\/j.clml.2019.10.014"},{"issue":"4","key":"4060_CR28","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/leu.2017.331","volume":"32","author":"SK Kumar","year":"2018","unstructured":"Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A (2018) Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 32(4):986\u2013995. https:\/\/doi.org\/10.1038\/leu.2017.331","journal-title":"Leukemia"},{"issue":"18","key":"4060_CR29","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJM199110313251809","volume":"325","author":"B Barlogie","year":"1991","unstructured":"Barlogie B (1991) Toward a cure for multiple myeloma? N Engl J Med 325(18):1304\u20131306. https:\/\/doi.org\/10.1056\/NEJM199110313251809","journal-title":"N Engl J Med"},{"issue":"2","key":"4060_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.clml.2013.11.009","volume":"14","author":"M Martino","year":"2014","unstructured":"Martino M, Postorino M, Gallo GA, Messina G, Neri S, Piro E, Gentile M, Moscato T, Monteleone R, Fedele R, Mazzone C, Console G, Penna G, Alati C, Vincelli ID, Irrera G, Musolino C, Ronco F, Molica S, Morabito F (2014) Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. Clin Lymphoma Myeloma Leuk 14(2):148\u2013154. https:\/\/doi.org\/10.1016\/j.clml.2013.11.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"4060_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/sj.bmt.1704757","volume":"35","author":"A Fassas","year":"2005","unstructured":"Fassas A, Shaughnessy J, Barlogie B (2005) Cure of myeloma: hype or reality? Bone Marrow Transplant 35(3):215\u2013224. https:\/\/doi.org\/10.1038\/sj.bmt.1704757","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4060_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/leu.2012.160","volume":"27","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, AlSayed Y, Vanrhee F, Barlogie B (2013) Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 27(1):226\u2013232. https:\/\/doi.org\/10.1038\/leu.2012.160","journal-title":"Leukemia"},{"issue":"6","key":"4060_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1365-2141.2007.06921.x","volume":"140","author":"M Pineda-Roman","year":"2008","unstructured":"Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD Jr, Barlogie B (2008) Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 140(6):625\u2013634. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06921.x","journal-title":"Br J Haematol"},{"issue":"4","key":"4060_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2141.2008.06982.x","volume":"141","author":"M Zangari","year":"2008","unstructured":"Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J, Barlogie B (2008) Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol 141(4):433\u2013444. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.06982.x","journal-title":"Br J Haematol"},{"issue":"10192","key":"4060_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Bene MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394(10192):29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1","journal-title":"Lancet"},{"issue":"3","key":"4060_CR36","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bjh.15806","volume":"185","author":"H Yimer","year":"2019","unstructured":"Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M, Stevens D, Gunawardena S, Lutska Y, Qi K, Ukropec J, Qi M, Lin TS, Rifkin RM (2019) Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 185(3):492\u2013502. https:\/\/doi.org\/10.1111\/bjh.15806","journal-title":"Br J Haematol"},{"issue":"15_suppl","key":"4060_CR37","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.1200\/JCO.2017.35.15_suppl.8000","volume":"35","author":"AJ Jakubowiak","year":"2017","unstructured":"Jakubowiak AJ, Chari A, Lonial S, Weiss BM, Comenzo RL, Wu K, Khokhar NZ, Wang J, Doshi P, Usmani SZ (2017) Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J Clin Oncol 35(15_suppl):8000. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.8000","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"4060_CR38","doi-asserted-by":"publisher","first-page":"TPS8055","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8055","volume":"37","author":"P Sonneveld","year":"2019","unstructured":"Sonneveld P, Broijl A, Gay F, Boccadoro M, Einsele H, Blade J, Dimopoulos MA, Delforge M, Spencer A, Hajek R, Schjesvold F, Lonergan S, Smith E, Carson RL, Crist W, Garvin WS, Vermeulen J, Moreau P (2019) Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): a multicenter, randomized, phase III study (PERSEUS). J Clin Oncol 37(15_suppl):TPS8055. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS8055","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"4060_CR39","doi-asserted-by":"publisher","first-page":"TPS8055","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS8055","volume":"36","author":"RZ Orlowski","year":"2018","unstructured":"Orlowski RZ, Goldschmidt H, Cavo M, Martin TG, Paux G, Oprea C, Facon T (2018) Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). J Clin Oncol 36(15_suppl):TPS8055. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.TPS8055","journal-title":"J Clin Oncol"},{"issue":"5347","key":"4060_CR40","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/bmj.1.5347.1704","volume":"1","author":"EC Easson","year":"1963","unstructured":"Easson EC, Russell MH (1963) Cure of Hodgkin's disease. Br Med J 1(5347):1704\u20131707. https:\/\/doi.org\/10.1136\/bmj.1.5347.1704","journal-title":"Br Med J"},{"issue":"10","key":"4060_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.100","volume":"6","author":"A Ravindran","year":"2016","unstructured":"Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, Hashmi SK, Marshall AL, Ashrani AA, Dispenzieri A, Kyle RA, Rajkumar SV, Go RS (2016) Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J 6(10):e486. https:\/\/doi.org\/10.1038\/bcj.2016.100","journal-title":"Blood Cancer J"},{"issue":"3","key":"4060_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV (2018) Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med 378(3):241\u2013249. https:\/\/doi.org\/10.1056\/NEJMoa1709974","journal-title":"N Engl J Med"},{"issue":"11","key":"4060_CR43","first-page":"1828","volume":"31","author":"E Frei 3rd","year":"1971","unstructured":"Frei E 3rd, Gehan EA (1971) Definition of cure for Hodgkin's disease. Cancer Res 31(11):1828\u20131833","journal-title":"Cancer Res"},{"issue":"10","key":"4060_CR44","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.4065\/83.10.1142","volume":"83","author":"SV Rajkumar","year":"2008","unstructured":"Rajkumar SV (2008) Treatment of myeloma: cure vs control. Mayo Clin Proc 83(10):1142\u20131145. https:\/\/doi.org\/10.4065\/83.10.1142","journal-title":"Mayo Clin Proc"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04060-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04060-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04060-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T23:30:49Z","timestamp":1620343849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04060-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["4060"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04060-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]},"assertion":[{"value":"26 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}